Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Purine Nucleoside. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN107698590A details asymmetric cyclization for high-purity nucleosides. Offers cost reduction in API manufacturing and scalable supply chain solutions.
Patent CN1380299A reveals a crystallization method replacing column chromatography for purifying nucleoside intermediates, offering significant cost and scalability advantages.
Patent CN105693725A reveals efficient asymmetric cycloaddition for high-purity nucleoside analogues, offering supply chain stability and cost reduction in API manufacturing.
Patent CN107827890A reveals dynamic kinetic resolution for high-purity chiral purine acyclic nucleosides offering supply chain reliability and cost reduction.
Patent CN102127135A reveals a mild, gold-catalyzed glycosylation method for pyrimidine and purine nucleosides, offering significant cost reduction in API manufacturing.
Patent CN113461743A reveals a cost-effective 4-step route for crosslinkable nucleosides, eliminating chromatography and enabling high-purity oligonucleotide manufacturing.
Patent CN110759957B reveals a novel KOH-catalyzed route for lipid-soluble isoguanosine intermediates, enhancing bioavailability and reducing purification costs for antisense therapies.
Patent CN109761984B details a novel ruthenium-catalyzed asymmetric hydrogen transfer method for synthesizing chiral purine nucleosides with high enantioselectivity and mild conditions.
Patent CN105732631A reveals efficient N9 vinyl purine synthesis. Offers cost reduction in pharmaceutical intermediates manufacturing with high yield and scalability.
Patent CN105418710B reveals a cost-effective route for 2,6-Dichloropurine Nucleoside. Enhance supply chain reliability with scalable pharmaceutical intermediates.
Patent CN107698590B details a novel asymmetric [3+2] cyclization for chiral carbocyclic purine nucleosides, offering high yields and enantioselectivity for reliable pharmaceutical intermediate supply.
Patent CN108558882B reveals a novel [3+2] cycloaddition route for chiral nucleosides, offering high enantioselectivity and streamlined manufacturing for pharmaceutical intermediates.
Patent CN109761984B reveals a novel asymmetric hydrogen transfer method for high-purity chiral purine nucleosides, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN110590781B reveals a novel Pd-catalyzed asymmetric allylic amination route for high-purity antiviral intermediates, offering significant cost reduction and scalable manufacturing capabilities.
Patent CN108912123B enables high-purity chiral nucleosides through asymmetric catalysis with simplified process and reduced manufacturing costs.
Patent CN109761984A enables high-purity chiral carbocyclic purine nucleosides synthesis via asymmetric hydrogen transfer. This method eliminates high-pressure hydrogenation systems while achieving up to 99% enantioselectivity and ensuring reliable pharmaceutical supply chains.
Patent CN109761984B enables high-purity API intermediates through asymmetric hydrogen transfer with enhanced supply chain reliability and reduced manufacturing costs.